ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Japan faces short supply of coronavirus drug remdesivir

Gilead Sciences to distribute enough to cover 140,000 patients worldwide

Some hope Gilead Sciences' Ebola drug remdesivir, left, can prove effective against the novel coronavirus. (Nikkei montage of Reuters/U.S. National Institute of Allergy and Infectious Diseases images)
JUNTARO ARAI, Nikkei staff writer | Japan

TOKYO -- Japan will not be able to receive a stable supply of promising coronavirus therapy remdesivir from its U.S. developer to treat all patients in need, Nikkei learned Friday.

Read Next

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more

By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our Cookie Policy to learn how you can update your cookie settings.

Accept & Continue Close